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Quality of lifeAbstract Background: Because of the narrow therapeutic index of digoxin, most cardiologists in
Egypt give digoxin holiday for atrial fibrillation and heart failure, it is not clear if the interrupted
digoxin regimens are effective since serum digoxin concentrations might fall below the therapeutic
range.
Objective: To evaluate and compare the digoxin serum concentration and patient’s quality of life in
the continuous versus interrupted digoxin dosing regimens.
Methods: Patients were randomized to receive one of four regimens: regimen 1: 0.25 mg daily
except Friday (N= 17); regimen 2: 0.25 mg daily except Thursday and Friday (N= 17); regimen
3: 0.125 mg daily (N= 17); and regimen 4: a tailored dose was calculated based on renal function
and given daily (N= 23). After reaching steady state in the two holiday regimens, two plasma sam-
ples were collected (preholiday and post holiday trough concentrations); in the other two groups
one trough plasma sample was collected. Quality of life questionnaire for atrial fibrillation (QLAF),
was administered to all patients at baseline and then after at least one month of digoxin therapy.
Results: There was a statistically significant difference between the preholiday trough concentra-
tion and the trough steady state concentration across the four regimens (p= 0.002). There was
no significant difference in the QLAF questionnaire domains, total scores at baseline, or after
the follow up between the four regimens.
Conclusion: Once daily tablet (0.25 mg) was suitable in maintaining digoxin serum concentration in
the recommended therapeutic range, fluctuation in digoxin serum concentration did not affect qual-
ity of life for atrial fibrillation patients.
 2016 Publishing services provided by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Digoxin is a cardiac glycoside prescribed in heart failure and
certain supraventricular tachyarrhythmias. It exerts a positive
inotropic, neurohormonal, and electro physiologic actions on
the heart.1 For heart failure patients, the targeted steady state
158 S.A. Alshabasy et al.serum digoxin level is between 0.5 and 0.8 ng/ml.2–6 Ventricular
rate control in atrial fibrillation patients will usually require
higher digoxin steady state serum concentrations.1 However,
serum digoxin level higher than 2 ng/ml is associated with an
increased incidence of adverse drug reactions and should be
avoided.1 Because of inter and intra-patient variability, narrow
therapeutic index, and risk of toxicity, digoxin doses are
calculated based on patient weight, renal status, indications
and drug interactions. Due to substantial overlap between
therapeutic and toxic levels of digoxin, therapeutic drug
monitoring is a must especially in patients with deteriorating
renal function and electrolyte disturbance.7–9 In Egypt, most
cardiologists give a digoxin holiday for patients with atrial
fibrillation and/or heart failure where patients skip the drug
doses on Thursday and Friday or Friday only every week to
avoid possible drug accumulation and toxicity. It is not clear
if these interrupted digoxin regimens really offer safer alterna-
tive over the continuous dosing regimens without compromis-
ing the effectiveness and patient quality of life. It is anticipated
that plasma digoxin levels may fall below the therapeutic range
during the holiday which may affect patient clinical status.
To the best of our knowledge this is the first study to assess
the quality of life (QoL) for atrial fibrillation patients taking
different digoxin treatment regimens.
The aim of our study is to evaluate and compare the contin-
uous versus interrupted digoxin dosing regimens by measuring
digoxin trough steady state plasma concentrations, evaluating
patients’ quality of life using quality of life questionnaire for
atrial fibrillation patients (QLAF),10 and using specific struc-
tured questions to evaluate signs and symptoms of digoxin side
effects and toxicity.
2. Materials and methods
2.1. Patients
Patients with atrial fibrillation (AF) with or without congestive
heart failure (CHF) taking digoxin tablets were enrolled from
the Egyptian National Heart Institute (NHI) outpatient’s clin-
ics, in the period between October 2012 and October 2014.
Patients were excluded if they were below 18 or above 70 year
old, taking the following drugs concurrently: amiodarone,
verapamil, quinidine and propafenone,6,11–13 diagnosed with
thyroid disorders (hyperthyroidism and hypothyroidism), with
creatinine clearance less than 10 ml/min, or pregnant. All
patients were on interrupted digoxin regimens before the study.
The study protocol was approved by the Faculty of
Pharmacy, Cairo University Ethics Committee. Written
informed consent was obtained from all patients. Clinical
trials.gov identifier (NCT02489786).
2.2. Study design
This was a prospective randomized parallel study. Randomiza-
tion was done by assigning a number for each subject and
using a table of random digits. Patients received one of four
regimens; either regimen 1: one tablet (0.25 mg) daily except
Friday, regimen 2: one tablet (0.25 mg) daily except Thursday
and Friday, regimen 3: half tablet (0.125 mg) daily), or regimen
4: a tailored daily dose was calculated according to the
patient’s renal function and ejection fraction.In addition, the following data were collected for each
patient: demographics, chief complaint, past medical history,
medication history, family history, social history, the previous
digoxin dosage regimen, echocardiography, electrocardio-
gram, serum creatinine, potassium (K+), calcium (Ca++),
and magnesium (Mg++) and physical examination at the
study baseline. A specific questionnaire to assess signs and
symptoms of digoxin toxicity as nausea, vomiting, diarrhea,
loss of appetite, fatigue, uneven heart beats (slow, fast),
blurred vision, seeing yellow or green halos around lights or
objects, skin rash, bloody black tarry stool was administered
at baseline and at least after one month of digoxin therapy.
A quality of life questionnaire (QLAF) with domains that
assessed the common symptoms and interventions of atrial fib-
rillation as palpitation, breathlessness, chest pain and dizzi-
ness, drugs, direct current cardio version and ablation10 was
administered as well. All patients received the same brand of
digoxin tablet (0.25 mg) for at least one month to ensure that
the steady state was reached. Monitoring of trough concentra-
tions (immediately before the next dose) was used for thera-
peutic digoxin monitoring.14 In the two groups of digoxin
holiday, two plasma samples were collected, for regimens 1
and 2 the preholiday trough samples were collected predosing
on Thursday and Wednesday respectively while the post holi-
day trough samples were withdrawn on Saturday for both reg-
imens. In the other two groups, one trough plasma sample was
collected at any day of the week. Samples were frozen at
20C15 and assayed with Enzyme Linked Fluorescent Assay
VIDAS DIGOXIN, BIOMEREUX SA, France with mea-
surement range 0.2–5 ng/ml. The tailored dose that was calcu-
lated and given daily was calculated using JUSKO–KOUP
method for digoxin dosing.16,17 Creatinine clearance in ml/
min was estimated from the patient’s serum creatinine using
Cockcroft and Gault equation.18 The target steady state
(CSS) used in calculating the digoxin dose was 0.9 ng/ml.
Digoxin compliance was assessed by phone calling the patients
twice weekly.
There is a direct relation between creatinine clearance and
digoxin clearance.
Cl ¼ 1:303ðCrClÞ þ ClNR ð1Þ
where Cl is digoxin clearance in ml/min. CrCl is creatinine
clearance in ml/min and ClNR is the digoxin clearance by
non-renal routes which equals 40 ml/min in patients with no
or mild heart failure (NHYA CHF class I or II) or left ventric-
ular ejection fraction (LVEF) >45%, and 20 ml/min in
patients with moderate or severe heart failure (NYHA CHF
class III or IV) or (LVEF) 645%.16,19,20
Maintenance dose was calculated using this formula:
D=s ¼ ðCSS  ClÞ=F ð2Þ
where D is the digoxin dose in lg, s is the dosage interval in
days, CSS is the desired steady state (CSS = 0.9 lg/l) and Cl
is digoxin clearance in L/d, F is the bioavailability constant
(F= 0.7 for the tablet).16,17
2.3. Statistical analysis
Statistical analysis was performed using SPSS software
package version 20. Categorical variables were reported as
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Figure 1 Flow diagram for patient enrollment.
Table 1 Patients, demographics expressed as number (percentages) or mean ± standard deviation.
Regimen 1 N= 17 Regimen 2 N= 17 Regimen 3 N= 17 Regimen 4 N= 23 P-value
Females 13 (76.5) 12 (70.6) 14 (82.4) 15 (65.2) 0.65
Age 45.7 ± 8.97 46.5 ± 9.4 47.8 ± 10.1 46.9 ± 8.8 0.94
Height (cm) 160.8 ± 9.9 163.0 ± 8.5 160.2 ± 8.1 161.7 ± 8.4 0.67
Weight (kg) 83.9 ± 23.96 76.1 ± 13.1 75.2 ± 13.9 76.2 ± 16.4 0.69
BMI (kg/m2) 32.4 ± 8.6 28.8 ± 5.9 29.3 ± 5.2 29.1 ± 5.0 0.44
Systolic B.P. 120.1 ± 17.5 130.1 ± 13.7 126.2 ± 16.5 122.5 ± 17.9 0.23
Diastolic B.P. 79.2 ± 14.6 80.8 ± 11.6 77.9 ± 14.1 76.2 ± 11.9 0.80
Heart rate (bpm) 87.3 ± 11.7 91.0 ± 10.99 84.4 ± 13.3 87.8 ± 17.2 0.59
RBG (mg/dl) 159.3 ± 56.6 129.1 ± 30.3 130.8 ± 34.4 126.7 ± 31.6 0.21
Smoker 0 1 (5.9) 0 1 (4.3)
Regimen 4 = adjusted renal function group (N= 19 took 0.25 mg daily, N= 1 took 0.125 mg daily, N= 3 took 0.375 mg daily), BMI = body
mass index, RBG= random blood glucose, B.P. = blood pressure.
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uous variables were expressed as mean ± standard deviation.
Normal distributions of parameters were assessed by Sha-
piro–Wilk test. One way analysis of variance (ANOVA) was
used followed by post hoc LSD test and paired student’s t test
was used for normally distributed continuous variables. Krus-
kal–Wallis test and Wilcoxon Signed Rank test were used for
the other variables. Pearson’s correlation was used. Reliability
of the QLAF was assessed using Cronbach’s alpha coeffi-
cient.21 Statistical significance was defined as p< 0.05.
3. Results
3.1. Demographics, laboratory and diagnostics
Twelve patients were excluded as they did not continue the fol-
low up period, a total of seventy four patients including twentymales completed the follow up (Fig. 1). All patients were diag-
nosed with atrial fibrillation. Eighteen patients suffered from
both congestive heart failure and atrial fibrillation. NYHA
classes were categorized based on ejection fraction.20,19 Three
patients were excluded from regimen 4 because of non compli-
ance. There was no significant difference in patients’ demo-
graphics, labs and diagnostic tests at baseline (Tables 1 and
2). There was no significant difference in the patients, weight,
heart rate and systolic blood pressure at baseline and after
the follow up period across the four regimens. Patients’ co-
morbidities and concurrent medications are shown in (Table 3).
3.2. Primary outcomes
3.2.1. Digoxin serum concentration
Preholiday trough concentration of the interrupted regimens
(regimen 1 and 2) and trough steady state concentration of
Table 2 Baseline laboratory values and diagnostics tests expressed as mean ± standard deviation or number (percentage).
Regimen 1 Regimen 2 Regimen 3 Regimen 4 P-value
Scr, mg/dl 0.96 ± 0.29 0.92 ± 0.28 0.91 ± 0.26 0.95 ± 0.17 0.928
eCrCl1 ml/min 84.4 ± 28.9 87.2 ± 27.8 82.9 ± 29.4 79.6 ± 22.3 0.68
K, mmol/l 4.55 ± 0.54 4.28 ± 0.39 4.62 ± 0.44 4.36 ± 0.51 0.141
Ca, mg/dl 9.69 ± 0.38 9.67 ± 0.53 9.56 ± 0.59 9.35 ± 0.61 0.223
Mg, mg/dl 2.3 ± 0.12 2.29 ± 0.17 2.27 ± 0.22 2.21 ± 0.27 0.892
LVEF (%) 53.8 ± 9.8 59.1 ± 9.5 53.7 ± 9.7 58.2 ± 9.3 0.2
NYHA classes
NYHA I (grade 0) 11 (73.3) 11 (73.3) 9 (60) 17 (81)
NYHA II (grade1) 2 (13.3) 1 (6.7) 3 (20) 2 (9.5) 0.6
NYHA III (grade2) 1 (6.7) 3 (20) 3 (20) 2 (9.5)
NYHA IV (grade 3) 1 (6.7) 0 (0) 0 (0) 0 (0)
ECG rhythm
Atrial fibrillation 17 (100%) 17 (100) 17 (100) 23 (100)
Scr = serum creatinine, eCrCl1 = estimated creatinine clearance using the Cockcroft and Gault equation, LVEF= left ventricular ejection
fraction, NYHA=New York Heart Association, ECG= Electrocardiogram. Significance level p value < 0.05.
Table 3 Baseline co-morbidities and concurrent medications expressed as number (percentage).
Regimen 1 Regimen 2 Regimen 3 Regimen 4
Diabetes 4 (23.5) 2 (11.8) 2 (11.8) 2 (8.7)
High B.P. 2 (11.8) 3 (17.6) 1 (5.9) 4 (17.4)
Hepatitis C 0 1 (5.9) 1 (5.9) 2 (8.7)
Hernia 2 (11.8) 0 0 3 (13)
Bone pain 2 (11.8) 6 (35.3) 3 (17.6) 3 (13)
Valve surgery 12 (70.6) 14 (82.3) 13 (76.5) 19 (82.6)
Rheumatic heart disease 2 (11.8) 2 (11.8) 2 (11.8) 3 (13)
Warfarin 17 (100) 17 (100) 17 (100) 23 (100)
ß-blocker 2 (11.8) 0 2 (11.8) 0
Furosemide 8 (47) 3 (17.6) 6 (35.3) 8 (34.8)
Spironolactone 6 (35.3) 3 (17.6) 4 (23.5) 2 (8.7)
ACE-inhibitors 1 (5.9) 3 (17.6) 1 (5.9) 2 (8.7)
Penicillin 0 3 (17.6) 1 (5.9) 3 (13)
Aspirin 1 (5.9) 1 (5.9) 0 0
Nitroglycerin 0 0 0 2 (8.7)
Statins 1 (5.9) 0 0 0
160 S.A. Alshabasy et al.the continuous regimens (regimen 3 and 4) were compared.
There were statistically significant differences across the four
regimens as determined by one way ANOVA (F(3, 67)
= 5.377, p= 0.002) (Fig. 2).
There was a statistically significant difference between reg-
imens 1 and 3 and regimens 3 and 4 (p-value = 0.001). There
was no statistically significant difference between regimens 1, 2
and 4 as compared by LSD.
There was no significant difference between preholiday
trough concentrations for regimens 1 and 2. However, for each
regimen there was a statistically significant decrease between
preholiday and post holiday trough concentrations (p-
value < 0.001) (Fig. 3) in addition to a statistically significant
decrease in the mean post holiday concentration of regimen 2
compared to regimen 1 (p-value = 0.013). (Fig. 3).
Since there is a concern that an increase in digoxin mortal-
ity may be associated with a higher serum digoxin concentra-
tion2,15,22,23, thus the therapeutic range between 0.5 and
1.2 ng/ml was deemed appropriate. For regimens 1 and 2,
82.4% and 58.8% of the patients had preholiday trough
concentration in the therapeutic range which decreased to52.9% and 17.6% post holiday respectively. For regimens 3
and 4, 47.1% and 90% of the patients had trough steady state
concentration within the therapeutic range, respectively
(Table 4).
3.3. Secondary outcomes
3.3.1. Quality of life assessment
QLAF was translated and administered twice to eleven
patients to assess its reproducibility. Cronbach’s alpha coeffi-
cients for palpitation, breathlessness, chest pain, dizziness,
and total QLAF scores were 0.67, 0.75, 0.85, 0.88, and 0.87
respectively. No patients underwent direct current cardio-
version or ablation. In the palpitation domain, in the first item
patients proposed adding two more options (2–3 times weekly
and with effort) and proposed adding one more option in the
second item (high activity).
QLAF was administered to all patients at baseline and at
least after one month of digoxin therapy in which higher scores
indicated worse quality of life. There was no statistically signif-
icant difference across the four regimens in the questionnaire
Figure 2 Digoxin preholiday trough concentration of the interrupted regimens and trough steady state concentration of the continuous
regimens (ANOVA,*Significant, p= 0.002).
Figure 3 Comparison between preholiday, post holiday trough
concentrations of the interrupted regimens (unpaired student’s t
test, *Significant, p= 0.013) in the post-holiday trough concen-
tration of regimen 1and 2.
Digoxin holiday dosing practice in Egypt 161domains and total scores at baseline and after the follow up of
digoxin therapy. However, there was a significant difference on
comparing the different questionnaire domains and totalTable 4 Preholiday, post holiday trough concentration of the inte
continuous regimens in the therapeutic range 0.5–1.2 ng/ml, expresse
Regimen 1 (N= 17) Regimen 2 (N=
Pre Post Pre
<0.5 1 (5.9) 8 (47.1) 5 (29.4)
0.5–1.2 14 (82.4) 9 (52.9) 10 (58.8)
>1.2 2 (11.8) 0 2 (11.8)scores for each regimen at baseline and after the follow up
(Table 5). In regimen 1, there was a significant improvement
in the palpitation, dizziness, drugs and total questionnaire
scores (p-value = 0.03, 0.02, 0.01, 0.02 respectively). In regi-
men 2, there was a significant improvement in the drugs
domain (p-value = 0.04). In regimen 3, there was a statistically
significant improvement in palpitation and total questionnaire
scores (p-value = 0.002, 0.01 respectively). In regimen 4, there
was a statistically significant improvement in palpitation and
breathlessness (p-value = 0.01, 0.04 respectively). There was
no significant correlation between digoxin serum concentra-
tion and the different questionnaire domain scores and total
scores.
3.3.2. Digoxin side effects
At study baseline only three patients suffered from the digoxin
side effects as nausea, fatigue, blurred vision, and uneven heart
beats. No other side effects were reported during the follow up
period.
4. Discussion
To the best of our knowledge this is the first study to assess
digoxin holiday dosing in the Egyptian population.
Digoxin is generally less effective for rate control than beta
blockers or calcium channel blockers, particularly during exer-
cise.24–28 Digoxin should not be used as a first line drug for raterrupted regimens and trough steady state concentration of the
d as number (percentage).
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162 S.A. Alshabasy et al.control.29,30 Therefore its use should be reserved only for
patients whose heart rate has not been adequately controlled
with the use of a beta blocker and/or calcium channel blocker
alone.31
There is some concern that digoxin is associated with an
increase in patient mortality, in which some studies show an
increase in mortality,22,23,32–34 while other studies show no
increase,35–37 finally the conclusion from a systemic review
and meta analysis of the literature suggest that digoxin use is
associated with an increased mortality risk especially among
patients with AF.38 The increase in mortality may be linked
to higher digoxin serum concentrations.2,15,22,23
This is the reason behind choosing a target serum concen-
tration of 0.9 ng/ml in calculating digoxin dose of regimen 4.
Although peak or trough levels can be used for digoxin level
monitoring,39,40 trough levels were found to strongly correlate
with patient clinical response. Therefore we used trough level
for monitoring of digoxin level.41 The trough was also used
to avoid having the patients wait for 6–8 h for optimum
digoxin peak concentration as the study was conducted in out-
patient clinics. The therapeutic range of 0.5–1.2 ng/ml was
used to compare between the four regimens. For the patients
who took 0.125 mg/day, only 47% of the patients were within
the therapeutic range, with the mean steady state concentra-
tion differing significantly from the other regimens. In regimen
4, 90% of the patients were within the range, which means that
calculating the dose based on creatinine clearance and patient’s
ejection fraction is the best way to maintain the patients in the
required therapeutic range.
The preholiday and post holiday trough concentrations
were measured to evaluate interrupted dosing regimen. The
preholiday mean trough concentration of regimen 1 and 2
did not differ significantly from regimen 4, meaning that both
regimens reached proper steady state serum (CSS) concentra-
tion on the last day before the holiday. However post holiday
concentrations tended to fall significantly in the two day holi-
day more than the one day holiday as expected.
In the one day holiday regimen (regimen 1) although 53%
of the patients had post holiday concentration in the recom-
mended therapeutic range, the efficacy of this regimen is still
questionable since it is not clear how long the patient digoxin
concentration remains sub-therapeutic.
However, this regimen is still regarded a convenient prac-
tice in Egypt for most settings in which calculating the proper
digoxin dose and therapeutic drug monitoring is not accessible
and for patients who experience higher digoxin serum concen-
trations despite the proper digoxin dosing.
The QLAF questionnaire was performed to assess the effec-
tiveness of the four regimens due to the lack of reliable tool to
assess the effectiveness of therapy in atrial fibrillation
patients.42 QoL was studied in heart failure patients in which
there was a significant improvement in the patients QoL with
continuous dosing regimens than the interrupted (two day hol-
iday) dosing regimens.43 In the present study there was no sig-
nificant difference in the different questionnaire domains, total
scores at baseline or even after the follow up across the four
regimens, meaning that fluctuation in digoxin serum concen-
tration did not affect the quality of life for atrial fibrillation
patients with the lack of significant correlation between the
digoxin serum concentration of the four regimens and the dif-
ferent questionnaire domains. For regimens 1, 3, and 4 there
was a significant improvement in the palpitation domain this
Digoxin holiday dosing practice in Egypt 163might be due to patients being more compliant due to follow
up. This improvement was not observed in regimen 2 patients.
This could be explained by the fact that the two day holiday
led to a decreased digoxin serum concentration at which the
heart rate was not controlled.
There was significant improvement in the breathlessness
domain in regimen 4 which, meant that maintaining the steady
state serum concentration in the therapeutic range led to the
improvement in the exercise capacity as supported previ-
ously.44 Although 90% of the patients in regimen 4 where
within the therapeutic range difference in effectiveness could
not be demonstrated by QLAF across regimens. Digoxin hol-
iday was studied in two previous studies, both recommended
daily digoxin regimens over interrupted regimens to avoid fluc-
tuation in the digoxin serum concentrations,41,45 with clinical
signs and symptoms not reliable to evaluate the different
digoxin regimens.41
We can conclude that calculating the proper dose based on
kidney function was superior to all other regimens in maintain-
ing the steady state in the therapeutic range. The two day hol-
iday leads to a great fluctuation in the digoxin serum
concentration with most patients falling below the therapeutic
range post holiday.5. Conclusion
Once daily tablet (0.25 mg) was suitable in maintaining digoxin
serum concentration in the recommended therapeutic range,
fluctuation in digoxin serum concentration did not affect
QoL for atrial fibrillation patients.
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